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A robust VMAT delivery solution for single-fraction lung SABR utilizing FFF
beams minimizing dosimetric compromise
Abstract
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on
behalf of American Association of Physicists in Medicine. Peripheral lung lesions treated with a single
fraction of stereotactic ablative body radiotherapy (SABR) utilizing volumetric modulated arc therapy
(VMAT) delivery and flattening filter-free (FFF) beams represent a potentially high-risk scenario for
clinically significant dose blurring effects due to interplay between the respiratory motion of the lesion
and dynamic multi-leaf collimators (MLCs). The aim of this study was to determine an efficient means of
developing low-modulation VMAT plans in the Eclipse treatment planning system (v15.5, Varian Medical
Systems, Palo Alto, USA) in order to minimize this risk, while maintaining dosimetric quality. The study
involved 19 patients where an internal target volume (ITV) was contoured to encompass the entire range
of tumor motion, and a planning target volume (PTV) created using a 5-mm isotropic expansion of this
contour. Each patient had seven plan variations created, with each rescaled to achieve the clinical
planning goal for PTV coverage. All plan variations used the same field arrangement, and consisted of
one dynamic conformal arc therapy (DCAT) plan, and six VMAT plans with varying degrees of modulation
restriction, achieved through utilizing different combinations of the aperture shape controller (ASC) in the
calculation parameters, and monitor unit (MU) objective during optimization. The dosimetric quality was
assessed based on RTOG conformity indices (CI100/CI50), as well as adherence to dose–volume metrics
used clinically at our institution. Plan complexity was assessed based on the modulation factor (MU/cGy)
and the field edge metric. While VMAT plans with the least modulation restriction achieved the best
dosimetry, it was found that there was no clinically significant trade-off in terms of dose to organs at risk
and conformity by reducing complexity. Furthermore, it was found that utilizing the ASC and MU objective
could reduce plan complexity to near-DCAT levels with improved dosimetry, which may be sufficiently
robust to overcome the interplay effect.

Disciplines
Engineering | Science and Technology Studies

Publication Details
Burton, A., Offer, K. & Hardcastle, N. (2020). A robust VMAT delivery solution for single-fraction lung SABR
utilizing FFF beams minimizing dosimetric compromise. Journal of Applied Clinical Medical Physics,

This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/4057

Received: 20 January 2020

|

Revised: 29 April 2020

|

Accepted: 30 April 2020

DOI: 10.1002/acm2.12919

TECHNICAL NOTE

A robust VMAT delivery solution for single‐fraction lung
SABR utilizing FFF beams minimizing dosimetric compromise
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Abstract
Peripheral lung lesions treated with a single fraction of stereotactic ablative body
radiotherapy (SABR) utilizing volumetric modulated arc therapy (VMAT) delivery and
ﬂattening ﬁlter‐free (FFF) beams represent a potentially high‐risk scenario for clini-
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cally signiﬁcant dose blurring effects due to interplay between the respiratory
motion of the lesion and dynamic multi‐leaf collimators (MLCs). The aim of this
study was to determine an efﬁcient means of developing low‐modulation VMAT
plans in the Eclipse treatment planning system (v15.5, Varian Medical Systems, Palo
Alto, USA) in order to minimize this risk, while maintaining dosimetric quality. The
study involved 19 patients where an internal target volume (ITV) was contoured to
encompass the entire range of tumor motion, and a planning target volume (PTV)
created using a 5‐mm isotropic expansion of this contour. Each patient had seven
plan variations created, with each rescaled to achieve the clinical planning goal for
PTV coverage. All plan variations used the same ﬁeld arrangement, and consisted of
one dynamic conformal arc therapy (DCAT) plan, and six VMAT plans with varying
degrees of modulation restriction, achieved through utilizing different combinations
of the aperture shape controller (ASC) in the calculation parameters, and monitor
unit (MU) objective during optimization. The dosimetric quality was assessed based
on RTOG conformity indices (CI100/CI50), as well as adherence to dose–volume
metrics used clinically at our institution. Plan complexity was assessed based on the
modulation factor (MU/cGy) and the ﬁeld edge metric. While VMAT plans with the
least modulation restriction achieved the best dosimetry, it was found that there
was no clinically signiﬁcant trade‐off in terms of dose to organs at risk and conformity by reducing complexity. Furthermore, it was found that utilizing the ASC and
MU objective could reduce plan complexity to near‐DCAT levels with improved
dosimetry, which may be sufﬁciently robust to overcome the interplay effect.
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target volume (PTV) was created by adding an isotropic 5 mm margin to the ITV. All treatment planning was performed in the Eclipse

Volumetric modulated arc therapy (VMAT) provides modulation via

treatment planning system (v15.5, Varian Medical Systems, Palo Alto,

continuous multileaf collimator (MLC) motion and dose rate modula-

USA) using the photon optimizer (v15.5). Dose calculation was per-

tion during gantry rotation.1,2 This complex delivery is derived

formed using the AcurosXB algorithm reporting dose to medium

through inverse planning, which provides the ability to tune the

(v15.5).

treatment plan dosimetry. Although modulated delivery is best uti-

Treatment plans using three arcs were created for each patient.

lized for complex target‐organ at risk geometry, VMAT is used for a

The selected beam arrangement ensured that both dosimetrically

range of treatment sites throughout the body.3–5 As an example,

acceptable dynamic conformal arc therapy (DCAT) and VMAT plans

peripheral lung stereotactic ablative body radiotherapy (SABR) vol-

were produced. Two coplanar 210° arcs on the ipsilateral side (typi-

umes are typically not complex in shape and in many cases are not

cal of VMAT), plus a 60° anterior noncoplanar arc delivered at couch

proximal to serial organs at risk, so there is little indication to create

90° (typical of DCAT at our institution) were used, with the isocen-

modulated plans. The main beneﬁts of using VMAT in this context

ter placed at the center of the target. Each plan used unique collima-

are highly efﬁcient delivery and in general a more efﬁcient planning

tor angles for each beam, ranging from ±5°to 45°. In each patient, all

process compared with 3D conformal treatments which require man-

plan types used identical jaw settings. All plans were rescaled to

ual tuning of beam weights. The main beneﬁts of VMAT in lung

match the coverage requirement of 99% of the PTV covered by pre-

SABR thus may be the use of variable dose rate and gantry speeds

scription dose (PTV D99% = 100%). All plans were developed using

that are produced by the optimizer, rather than complex aperture

the clinical 6 MV FFF beam model allowing up to 1400 MU/min, for

shapes.

a Varian TrueBeam (TB) or TrueBeam STx (TBSTx), with the Millen-

When delivering modulated treatments to moving targets, there
is a potential risk of interplay between tumor and MLC motion.

nium 120 MLC (5 mm central leaves) or Millennium HD 120 MLC
(2.5 mm central leaves), respectively.

Extensive research has shown this has limited impact in conventional

The optimization parameters tested to reduce modulation com-

fractionation due to the effects “blurring out” over the course of

plexity were the aperture shape controller (ASC) and the monitor

treatment; however, when using SABR which is typically delivered in

unit (MU) objective. The ASC deﬁnes aperture complexity by con-

6,7

Interplay‐in-

straining the difference in allowable positions for adjacent leaves.

duced dose discrepancies increase with decreasing number of

There are six settings ranging from “None” (no constraints) to “Very

breathing cycles completed by the patient during the treatment

High” (maximum constraint), which must be applied prior to entering

beam‐on time.6–8 Reducing aperture complexity,7,8 increasing the

the optimizer. The MU objective can be applied in the optimization

6,8

and

environment and allows the user to deﬁne a minimum and maximum

treating with higher dose per fraction have been shown to reduce

target MU for the plan. A penalty is applied to the optimizer cost

1–5 fractions this fractionation beneﬁt may not hold.

number of beams and fractions,

8,9

reducing the dose rate,

the risk of clinically signiﬁcant interplay effects.6,8,10 Furthermore,

function if the planned MU are not within the deﬁned range, and

some studies also suggest that the risk of clinically signiﬁcant inter-

this penalty is weighted by the “strength” assigned to the MU objec-

play effects increase with tumor motion amplitude.9,11 Limited data

tive (a value between 0 and 100). This allows the MU objective to

exists, however, for ﬂattening ﬁlter‐free (FFF) dose rates and single

be used as a tool for creating efﬁcient plan delivery, and therefore,

fractions >18 Gy.6–8,10 This means that single fraction lung cases

its success was measured based on the level of reduction to plan

treated with FFF beams represent a potentially high‐risk scenario,

complexity, rather than ability to achieve the a speciﬁc target MU.

and that reductions in aperture complexity are highly desirable to

The application of these parameters was compared to a previously

retain the beneﬁts of VMAT while limiting the dosimetric impact.

established method of modulation reduction known as “hybrid

The aim of this planning study was to determine an efﬁcient means

VMAT” (hVMAT).

of developing low‐modulation VMAT plans in order to minimize the

Each plan variation was created from an initial VMAT plan devel-

risk of interplay for single fraction lung SABR with high dose‐rate

oped following standard institutional procedure in order to establish

FFF beams.

the appropriate optimization objectives, to be used in all subsequent
VMAT plans. Jaws were set by ﬁrst ﬁtting the MLC to the PTV with
a 3 mm margin, and then using the Varian recommended jaw set-

2 | MATERIALS AND METHODS

tings which positions them 2 mm from the most extended leaf.
These plans used the institutional default ASC setting of “Moderate.”

We selected 19 sequential lung SABR patients treated with a single

Other ASC settings were applied by copying this plan, changing the

28 Gy fraction at our institution. Each patient was simulated using a

setting, and reoptimizing from new with all other objectives and set-

4DCT, with an internal target volume (ITV) contoured on the average

tings held constant, and no user interaction. The DCAT plan was cre-

intensity projection (AIP) while referencing the individual phases of

ated by copying the ﬁrst VMAT plan, replacing the MLC with

the 4DCT and the maximum intensity projection (MIP). The AIP was

conformal MLCs, and recalculating the dose using the VMAT ﬁeld

used for contouring, planning, and dose computation. ITV volumes

weights. In order to apply the MU objective, a two stage optimiza-

ranged from 0.3 to 20.3 cm3 (average 4.8 cm3), and the planning

tion was performed. That is, a VMAT plan (with the desired ASC
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setting) was used as the starting point, before reoptimizing with the

reduction. The MU objective was applied in combination with two

desired MU objective applied, selecting the “continue optimization

ASC settings (“Moderate” and “Very High”). The DCAT and ASC =

using current plan as base dose” option (which only proceeds

“None” VMAT plans were included for comparison to the least and

through multiresolution levels 3 and 4 of optimization) with no fur-

most modulated plans, respectively, and the ASC = “None” plan was

ther user interaction.. The hVMAT plan was created using the DCAT

used as the benchmark case for dosimetric comparison. All plan

plan as the starting point, before reoptimizing, and once again select-

types were renormalized to achieve the target coverage goal of PTV

ing the “continue optimization” option with no further user interac-

D99% = 100%.

tion. This has a similar effect to applying the MU objective because

Target doses were evaluated using the ITV D2% (as normaliza-

the DCAT plan used as a starting point has signiﬁcantly less MU

tion was performed using coverage). The dose conformity was

than a standard VMAT. The hVMAT method for modulation suppres-

assessed using the RTOG 100% and 50% conformity indices (CI100

sion, however, requires both an initial VMAT plan (to provide the

and CI50, respectively). The lung V5Gy, V20Gy, chest wall D30cc,

optimization objectives), and a DCAT plan (to provide the target

chest wall D0.5cc, spinal canal D0.5cc, esophagus, D0.5cc and skin

MU), and is therefore a less efﬁcient process than utilizing the MU

D0.5cc were also measured, and compared to the dose‐volume limits

objective.

used in a recent clinical trial.12 Plan complexity/robustness was eval-

Analysis was performed on a total of 19 sets of plans — 9 using

uated using the modulation factor (MF) deﬁned as the monitor units

the TBSTx model and 10 using the TB model. The optimum MU

per cGy (MU/cGy) and the edge metric (EM). The EM utilized was

objective settings (maximum MU = 40% of original, strength = 80)

based on the aperture complexity metric described in reference,13

were determined by trialing a broad combination of settings on the

applying the recommended weight of zero to the leaf ends when cal-

TBSTx patients (see Table A1, Appendix A). Note that the input max-

culating the aperture perimeter. A lower EM means reduced com-

imum MU is determined as a fraction (%) of the original MU. These

plexity, but is not strictly a measure of aperture openness. All

were the most penalizing settings trialed, and were selected to

dosimetric and plan complexity metrics were extracted using the

assess the maximum plan quality detriment as a result of modulation

Eclipse Scripting Application Programming Interface (API).

T A B L E 1 Average (±1SD) for each tested outcome across all plan types.
Metric

Planning goal

VMAT noASC
Avg (±1SD)

VMAT_mod
Avg (±1SD)

VMAT_Vhigh
Avg (±1SD)

DCAT
Avg (±1SD)

Mod_40_80
Avg (±1SD)

Vhigh_40_80
Avg (±1SD)

hVMAT
Avg (±1SD)

ITV D2% (Gy)

>35
<40

35.74
±1.27

35.73
±1.15

35.79
±1.15

34.63 ± 1.36*

34.94
±1.03*

35.42
±1.32

35.04 ± 1.03*

RTOG
CI100

<1.2‐1.3

1.12
±0.06

1.12
±0.06

1.13
±0.06

1.67
±0.28*

1.14
±0.13

1.28
±0.17*

1.26
±0.13*

RTOG
CI50

ALARA (<~6)

4.97
±0.78

5.05
±0.75

5.19
±0.78

7.61
±1.45*

5.71
±1.4*

6.52
±1.36*

6.50
±1.4*

Lungs
V5Gy (%)

<60

7.30
±4.1

7.41
±4.13

7.52
±4.15

8.66
±4.55

7.90
±4.42

8.32
±4.14

8.27
±4.42

Lungs
V20Gy (%)

<20

0.92
±0.61

0.94
±0.63

0.96
±0.64

1.38
±0.88

1.05
±0.76

1.16
±0.66

1.18
±0.76

ChestWall D30cc (Gy)

<30

7.94
±3.54

8.00
±3.63

7.98
±3.61

9.80
±4.67

8.31
±3.96

8.69
±3.69

8.83
±3.96

ChestWall D0.5cc (Gy)

<28

22.38
±9.13

22.30
±9.23

22.40
±9.21

25.47 ± 10.05

21.97
±8.78

23.04
±9.05

22.91 ± 8.78

SpinalCanal D0.5cc (Gy)

<12

2.59
±1.08

2.74
±1.23

2.84
±1.22

2.92
±1.13

2.80
±1.07

2.73
±1.12

2.73
±1.07

Esophagus D0.5cc (Gy)a

<15.4

2.70
±1.51

2.80
±1.39

2.83
±1.49

2.82
±1.43

2.56
±1.27

2.62
±1.41

2.62
±1.27

Skin
D0.5cc (Gy)

<24

8.46
±2.69

8.26
±2.75

8.38
±2.6

10.10
±3.5

8.46
±3.23

8.87
±2.72

9.36
±3.23

MF
(MU/cGy)

NA

2.97
±0.39*,Δ

2.85
±0.39*,Δ

2.69
±0.37*,Δ

1.68
±0.15*

2.11
±0.22*,Δ

1.96
±0.20*

1.87
±0.20*

NA

0.21
±0.04Δ

0.18
±0.03*,Δ

0.15
±0.03*,Δ

0.06
±0.01*

0.10
±0.02*,Δ

0.07
±0.02*

0.08
±0.02*

EM

Note: that this data is averaged across both beam models. A statistically signiﬁcant difference to the VMAT_noASC result is indicated by an asterisk (*).
For the robustness metrics, a statistically signiﬁcant difference to the DCAT result is shown by a delta (Δ).
a
Only 13 cases had the esophagus contoured.
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F I G . 1 . (a) Skin D0.5cc for each plan type and beam model. The
skin dose for the TB model is systematically higher for all plan types.
(b) Edge metric (EM) for each plan type and beam model. The EM
for the TBSTx model is systematically higher than for the TB model,
but this difference decreases as the EM decreases. (c) Modulation
factor for each plan type and beam model. There is negligible
difference in modulation factors between the two models in each
plan type.
The average and standard deviation of each endpoint were
determined for each plan type. Furthermore, the average difference
of each metric from the benchmark plan (VMAT_noASC) was determined for each plan type, and a paired Student’s t‐test was performed to determine the statistical signiﬁcance of this difference.
Additionally, the robustness metrics (EM and MF) for each plan type
were compared to the DCAT plan using a paired Student's t‐test.
The analysis was performed grouping both the TB and TBSTx data
together; however, an assessment of the difference between the
two models was also performed.

3 | RESULTS
Table 1 presents the mean (±1SD) outcome for each metric alongside the clinical planning goal, for each plan type. Each plan type
was compared with the benchmark plan (VMAT_noASC) via a paired
Student’s t‐test (P < 0.05). The ITV D2% was lower than the benchmark case for the DCAT, MU objective, and hVMAT plans, with the
maximum difference occurring in the DCAT plans. Similarly, the same
four test plans had larger conformity indices, while the VMAT plans
utilizing different ASC settings alone did not. On average, OAR
dose–volume metrics in the test plans were higher than for the
benchmark plan, but none of these differences were statistically signiﬁcant. For every plan type, the EM and MF were signiﬁcantly
lower than the benchmark case (with the exception of the MF for
the VMAT with “Moderate” ASC).
Overall, there were no data to suggest a signiﬁcant dosimetric
difference between the TB and TBSTx model; however, there were
some noteworthy exceptions. The skin D0.5cc using the TBSTx
model was systematically lower than the TB model for all plan types,
as depicted in Fig. 1(a). This is likely attributed to the TB patients

T A B L E 2 Comparison of average EM for each beam model by plan
type.
Plan type

TB EM Avg (±1SD)

TBSTx EM Avg (±1SD)

VMAT_noASC

0.18 ± 0.02

0.25 ± 0.03

VMAT_mod

0.16 ± 0.02

0.20 ± 0.03

VMAT_Vhigh

0.14 ± 0.02

0.17 ± 0.04

DCAT

0.06 ± 0.01

0.07 ± 0.02

Mod_40_80

0.10 ± 0.02

0.10 ± 0.03

Vhigh_40_80

0.07 ± 0.01

0.08 ± 0.02

hVMAT

0.07 ± 0.01

0.08 ± 0.02
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having more peripheral lesions, closer to the Skin contour, since the

off in terms of OAR doses. When it comes to target dose and con-

data did not suggest that the TB plans were more complex/modu-

formity, however, there is some compromise for penalizing modula-

lated overall. Rather, the TBSTx EM was systematically higher than

tion (see Fig. 2). All DCAT, MU objective and hVMAT plans showed

the TB model [Fig. 1(b)], in particular for the more modulated plan

deviations from the benchmark plan in the ITV D2%, CI100, and

types. This was expected since the TBSTx plans use a greater num-

CI50 quality metrics; however, the absolute outcomes of these met-

ber of leaf pairs to deﬁne each aperture, and thus introduce more

rics are clinically acceptable in all VMAT plans (Table 1).Depending

leaf edges to the EM calculation. Despite this, the mean EMs for the

on the patient speciﬁc tumor to OAR geometry, this dosimetric trade

DCAT, MU objective, and hVMAT plans are comparable for both

off may not be appropriate and other options to reduce susceptibil-

models (see Table 2).

ity to interplay effects may need to be taken.

Due to the open apertures, DCAT is the most robust to tumor

While the EM is strictly speaking a measure of aperture irregular-

motion of the plans investigated in this study, but the data in Table 1

ity, it can be used as a measure of VMAT aperture openness by

shows that DCAT is generally dosimetrically inferior to VMAT plan

comparison to the DCAT result (Table 1). In order for two plans to

types. The robustness metrics for the MU objective and hVMAT

have the similar EM they must have a similar ratio of open to par-

plans, however, were comparable to that of DCAT, as depicted in

tially blocked control points when MU weight is considered. Since

Figs. 1(b) and 1(c). The statistical testing conﬁrmed that both the

DCAT plans have only fully open apertures, a VMAT plan with a

hVMAT plan and MU objective plan with “Very High” ASC showed

comparable EM must have negligible partially blocked, irregular aper-

no signiﬁcant difference to DCAT (with the MU objective plus

tures. This conclusion is consistent with the results of measurement‐

“Moderate” ASC only slightly different) in the robustness metrics.

based interplay studies in the literature.9,11 In the context of the
small ﬁelds used in SABR, if the total MU (or MF) for both plans are
also similar, then they must have similar openness. In this way, we

4 | DISCUSSION

can be conﬁdent that the EM and MF are useful as a proxy for aperture openness. The use of the MU objective as described (maximum

The VMAT with ASC set to “None” plan type was chosen as the

MU = 40% of original, strength = 80) in combination with the “Very

benchmark to illustrate the maximum achievable dosimetric plan

High” ASC may therefore be appropriate for single fraction lung

quality, allowing the optimizer the most modulation. The results sug-

SABR treatments using FFF beams at high repetition rate, as the

gest that all plans tested have signiﬁcantly less modulation than

apertures may be sufﬁciently open to increase robustness to the

these unconstrained VMAT plans, and there is little dosimetric trade‐

interplay effect.

F I G . 2 . Example isodose distributions at the isocenter (internal target volume in red, planning target volume in cyan) for each plan type for
the same patient.
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5 | CONCLUSION
We have demonstrated signiﬁcant reductions in modulation com-

8.

plexity through use of aperture shape controller and monitor unit
restriction for lung SABR VMAT plans. These reductions were

9.

achieved with minimal dosimetric penalty, and may increase robustness to respiratory motion interplay effects in single fraction SABR

10.

with high dose rates observed with FFF beams.
11.
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T A B L E A 1 Combination of metrics trailed on ﬁrst 10 TBSTx
patients.
MU objective
Plan type

ASC

Max MU

Strength

DCAT

NA

NA

NA

VMAT

None, moderate, high, very high

NA

NA

hVMAT

Moderate, high, very high

NA

NA

VMAT with

Moderate, high, very high

40%

80

MU objective

Moderate, high, very high

60%

95

Moderate, high, very high

70%

100

